The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience.
 
Lisa M. Gashonia
Employment - TG Therapeutics
Stock and Other Ownership Interests - TG Therapeutics
 
Joseph R. Carver
Consulting or Advisory Role - Onyx
 
Rupal O'Quinn
No Relationships to Disclose
 
Suparna Clasen
No Relationships to Disclose
 
Mitchell E. Hughes
No Relationships to Disclose
 
Stephen J. Schuster
Consulting or Advisory Role - Celgene; Gilead Sciences; Nordic Nanovector; Novartis; Pharmacyclics
Research Funding - Celgene (Inst); Gilead Sciences (Inst); Johnson & Johnson (Inst); Novartis (Inst); Pharmacyclics (Inst)
 
Krista Isaac
No Relationships to Disclose
 
Kaitlin Kennard
No Relationships to Disclose
 
Jakub Svoboda
Consulting or Advisory Role - Seagen
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Pharmacyclics; Seagen
Travel, Accommodations, Expenses - Merck
 
Catherine Daniel
No Relationships to Disclose
 
Donald Edward Tsai
No Relationships to Disclose
 
Molly J Fanning
No Relationships to Disclose
 
Sunita Nasta
Research Funding - Millennium
 
Daniel Jeffrey Landsburg
No Relationships to Disclose
 
Chadi Nabhan
Employment - Cardinal Health
Leadership - Cardinal Health
Stock and Other Ownership Interests - Cardinal Health
 
Anthony R. Mato
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); DTRM (Inst); Gilead Sciences (Inst); Pharmacyclics (Inst); Regeneron (Inst); TG Therapeutics (Inst)